The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery
Open accessAbstract
Impressive progress in genome sequencing, protein expression and high-throughput crystallography and NMR has radically transformed the opportunities to use protein three-dimensional structures to accelerate drug discovery, but the quantity and complexity of the data have ensured a central place for informatics. Structural biology and bioinformatics have assisted in lead optimization and target identification where they have well established roles; they can now contribute to lead discovery, exploiting high-throughput methods of structure determination that provide powerful approaches to screening of fragment binding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
Self-citationFriesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
A new approach to protein fold recognition
Jones, D. T., Taylort, W. R., & Thornton, J. M. (1992) · Nature · doi:10.1038/358086a0 · Cited by 1,221 · cited 2×
“Threading, on the other hand, fits a probe sequence onto the backbone of a known structure, evaluating the compatibility between the sequence and the proposed structure by means of a set of empirical potentials, which are derived from wellresolved protein structure data ( Jones et al. 1992).”
BackgroundInsights into DNA recombination from the structure of a RAD51–BRCA2 complex
Pellegrini, L., Yu, D. S., Lo, T., Anand, S., Lee, M., Blundell, T. L., & Venkitaraman, A. R. (2002) · Nature · doi:10.1038/nature01230 · Cited by 704 · cited 2×
“A further example (figure 8) involves the complex of the human recombinase, Rad51, and the product of the breast cancer associated gene, BRCA2 (Pellegrini et al. 2002), which is not only revealing in terms of the nature of the interactions and the molecular origins of cancers associated with mutations in this region o…”
BackgroundSelf-citation
Cited by
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.020 · Cited by 1,311
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Homology modeling in drug discovery: current trends and applications
Cavasotto, C. N., & Phatak, S. S. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.04.006 · Cited by 483
Cryo-EM in drug discovery: achievements, limitations and prospects
Renaud, J.-P., Chari, A., Ciferri, C., Liu, W.-T., Rémigy, H.-W., Stark, H., & Wiesmann, C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.77 · Cited by 461
Mitosis-targeted anti-cancer therapies: where they stand
Chan, K.-S., Koh, C.-G., & Li, H.-Y. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.148 · Cited by 305
Metadata
- Authors
- Blundell, T. L., Sibanda, B. L., Montalvão, R. W., Brewerton, S., Chelliah, V., Worth, C. L., Harmer, N. J., Davies, O., & Burke, D.
- Venue
- Philosophical Transactions of the Royal Society B: Biological Sciences
- Publisher
- The Royal Society
- Published
- 2006-02-03
- Volume
- 361
- Issue
- 1467
- Pages
- 413-423
- ISSN
- 0962-8436 (ISSN-L)
- 1471-2970
- OpenAlex
- W2143411881
- Cited by
- 177
- References
- 5
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.